Study on High-Dose Spironolactone in Acute Heart Failure Patients

The ATHENA-HF trial investigates the impact of high-dose spironolactone on reducing NT-proBNP levels in acute heart failure patients. Key objectives include assessing congestion, dyspnea relief, urine output, weight change, diuretic requirement, and outcomes like mortality and readmissions up to 60

0 views • 20 slides